Bijender Kumar

Findings from a Phase I trial suggest natural killer cells pre-complexed with AFM13 has promise for specific patients with lymphoma and may be adapted for more cancer types in the future. Learn more: brnw.ch/21wRN45 #EndCancer

Dear Leukemia friends, making U aware of this exceptional MDS symposium organized by Dr. @CollaSimona at @MDAndersonNews in May 2025! The speaker line up is phenomenal & the science is cutting edge. Register 👇🏼 join us & RT pls mdanderson.cloud-cme.com/course/courseo… #MDSsm

Today, @MDAndersonNews launched the Institute for Cell Therapy Discovery & Innovation, which aims to lead the world in developing and advancing cell therapies for patients in need. By uniting top scientists and clinicians, we look forward to uncovering new insights in immunology and cell engineering, fueling the creation of transformational new treatments for cancer, autoimmune diseases, infections and other conditions.

Excited to share our manuscript published in @ScienceTM, where we describe a novel NK immune evasion strategy in AML. We found that #BATF is a key transcription factor driving epigenetic reprogramming in NK cells in AML. This TF is induced by the canonical TGF-β/SMAD pathway and leads to persistent NK cell dysfunction. This dysfunction can be prevented by deleting BATF or TGFBR2 upstream, but once established, it cannot be reversed. Designed to overcome epigenetic scarring, we look forward to bringing this novel CAR-NK cell approach to the clinic to improve outcomes for AML patients. @mdandersonnews @lab_rezvani @bijender2050 #AML #NK #CRISPR #epigenetics #BATF

Excited to share our manuscript published in @ScienceTM, where we describe a novel NK immune evasion strategy in AML. We found that #BATF is a key transcription factor driving epigenetic reprogramming in NK cells in AML. This TF is induced by the canonical TGF-β/SMAD pathway and leads to persistent NK cell dysfunction. This dysfunction can be prevented by deleting BATF or TGFBR2 upstream, but once established, it cannot be reversed. Designed to overcome epigenetic scarring, we look forward to bringing this novel CAR-NK cell approach to the clinic to improve outcomes for AML patients. @mdandersonnews @lab_rezvani @bijender2050 #AML #NK #CRISPR #epigenetics #BATF

Many congratulations to our Dr. Sunil Acharya @sunilacharya13 for his exciting research on CD70-targeting CAR NK cells, published in Cancer Discovery! Sunil and his co-authors showed that the incorporation of CD28 costimulation, which is normally absent in NK cells, in the CAR construct improves efficacy of CAR NK cells via the LCK/CD3ζ/ZAP70 pathway. Sincere thanks to our collaborators for their invaluable contributions. We’re excited about the promising clinical trials ahead! @MDAndersonNews #CancerResearch #Immunotherapy #CAR_NKCells @kchenken @UH_NVLab

🌐 @rftbsr9 introduces the versatile world of CAR-NK cells at #ESHCLL2024, spotlighting their benefits in treatment strategies, not just for #CLL but potentially beyond. With the capacity for various modifications and combinations, CAR-NK cells open new avenues in immunotherapy.